BDGT services are divided into molecular diagnostics and clinical services.

The molecular diagnostics laboratory delivers specialized diagnostic testing for blood and other monogenic disorders. Key services include carrier detection, prenatal diagnosis, exome- and soon genome-wide variant analysis (WES, WGS), non-invasive prenatal testing (NIPT), and pre-implantation genetic testing for monogenic disorders (PGT-M). PGT-M is offered also for non-hematological disorders and for many analyses is already based on long-read massively parallel sequencing. 

In close collaboration with the national screening laboratory and the thalassemia clinics, BDGT activities concerning hemoglobinopathies are part of the national thalassemia prevention program and provide central national molecular analyses. Through the partnership of CING with Makarios III Hospital Nicosia, as a Healthcare Provider within the European Reference Network EuroBloodNet, BDGT services for hemoglobinopathies are delivered as a center of excellence (Investigators: Thessalia Papasavva, PhD; Stefania Byrou, PhD).

Clinical services focus on the diagnosis and management of inherited/genetic blood disorders, such as rare red blood cell defects, bone marrow failure syndromes, immune disorders, rare bleeding-coagulation disorders, disorders of iron metabolism and heme synthesis, and syndromes with genetic predisposition to hematological malignancies. (Hematologist/Investigator: Panayiota L. Papasavva, MD, PhD).